Volume 19, Number 3—March 2013
Synopsis
Human Leptospirosis Trends, the Netherlands, 1925–2008
Marga G.A. Goris
, Kimberly R. Boer, Tamara A.T.E. Duarte, Suzanne J. Kliffen, and Rudy A. Hartskeerl
, Kimberly R. Boer, Tamara A.T.E. Duarte, Suzanne J. Kliffen, and Rudy A. Hartskeerl
Table 3
Treatment course and deaths, by infecting Leptospira spp. serogroups, for case-patients with leptospirosis, the Netherlands, 1925–2008*
| Serogroup | No. patients | No. (%) hospitalized | No. (%) treated with dialysis | No. (%) treated in ICU | No (%) died |
|---|---|---|---|---|---|
| Icterohaemorrhagiae | 1,702 | 1,311 (77.0) | 90 (11.9) | 68 (7.0) | 90 (5.3) |
| Grippotyphosa | 196 | 124 (63.3) | 3 (2.2) | 2 (1.2) | 0 |
| Sejroe | 128 | 48 (37.5) | 3 (2.4) | 2 (1.6) | 1 (0.8) |
| Canicola | 93 | 60 (64.5) | 0 | 0 (0.0) | 3 (3.2) |
| Pomona | 54 | 40 (74.1) | 3 (5.6) | 7 (13.0) | 0 |
| Other | 81 | 55 (67.9) | 3 (3.8) | 6 (7.6) | 1 (1.9) |
| Unknown | 299 | 213 (71.2) | 17 (8.6) | 21 (9.3) | 71 (23.7) |
*ICU, intensive care unit. Data were available for 2,553 patients who were hospitalized or died, 1,360 patients treated with dialysis, and 1,641 patients treated in an ICU.
Page created: February 13, 2013
Page updated: February 13, 2013
Page reviewed: February 13, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.